(Alliance News) - 4d Pharma PLC on Monday reported additional data from a probe of its Blautix treatment, which has been found to improve symptoms in sufferers of irritable bowel syndrome.
4d Pharma posted "encouraging" topline results from a phase II BHT-II-002 trial back in October.
A deeper dive into the data has found Blautix offered a "strong and statistically significant activity on the key symptom of bowel habit".
"4D pharma has been able to review the data in more detail. We have also discussed the results with internationally renowned key opinion leaders and patient groups. We are encouraged by the positive outcomes of this additional analysis, and we strongly believe that this signal finding study supports the continued development of Blautix as a novel treatment for IBS," Chief Scientific Officer Alex Stevenson said.
There were "consistent improvements in bowel habit" in patients that used Blautix.
Shares in the company were 1.3% higher at 98.30 pence each in London on Monday morning.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
